ArticleTranslational cancer research2025
Correlation between the decreased expression of NUDT18 and tumor progression in endometrial cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The multifaceted regulatory roles of Nudix hydrolases in cancer and their therapeutic potential.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nudix hydrolase 18 (NUDT18) belongs to the family of nudix hydrolases. This study aimed to clarify the relationship between NUDT18 and endometrial cancer (EC) and whether it is a prognostic factor for EC. Methods: We first examined the function of NUDT18 through The Cancer Genome Atlas public data and Human Protein Atlas databases, and then immunohistochemical staining was conducted to compare the expression of NUDT18 in normal endometrium and EC tissues of different stages. Finally, we performed gene set enrichment analysis (GSEA) to identify the signaling pathways regulated by NUDT18 in EC. Results: We found that NUDT18 expression was considerably elevated in EC tissues relative to physiological endometrium (P<0.001). However, Kaplan-Meier analysis revealed that high NUDT18 expression in EC was associated with a longer overall survival (OS). Immunohistochemistry results showed that NUDT18 expression was upregulated in tissues of early-stage EC compared with normal endometrial tissues and gradually decreased with the increase of stage. NUDT18 expression was significantly associated with Federation of Gynecology and Obstetrics stage, histologic grade, and myometrial invasion (all P values <0.05). GSEA revealed that the biological pathways that were differentially downregulated in the NUDT18-high expression phenotype were cell cycle, the TGF-β signaling pathway, RNA degradation, adherens junction, basal transcription factors, and DNA replication. In addition, NUDT18 DNA copy gain and the downregulation of miR-758-3p exhibited a correlation with the upregulation of NUDT18 in EC, and NUDT18 expression was significantly reduced in tumors with the TP53 mutation. The analysis of immune cell abundance indicated a substantial increase in immune infiltration in EC tissues with high NUDT18 expression. Conclusions: NUDT18 was upregulated in EC relative to normal endometrium, and its expression inversely correlated with tumor stage. Notably, higher NUDT18 expression predicted improved OS, highlighting its clinical significance as a marker of favorable prognosis in EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.